1103.3000 -2.00 (-0.18%)
NSE Sep 22, 2025 15:44 PM
Volume: 34,943
 

1103.30
-0.18%
ICICI Securities Limited
Tatva Chintan Pharma Chem’s (TATVA) revenue grew 7.3% QoQ, but gross profit margin collapsed to just 45.9% (vs 57.8% in Q4FY24) due to high-cost inventory, particularly in SDA, where it had to take 15-20% price.
Tatva Chintan Pharma Chem Ltd. has gained 20.27% in the last 3 Months
More from Tatva Chintan Pharma Chem Ltd.
Recommended